Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
93 hedge funds and large institutions have $272M invested in Merrimack Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 20 closing their positions.
241% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $731K
36% more capital invested
Capital invested by funds: $200M → $272M (+$71.9M)
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
2% less funds holding
Funds holding: 95 → 93 (-2)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.97M |
| 3 |
Morgan Stanley
New York
|
+$3.45M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.61M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8.45M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$5.34M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.91M |
| 4 |
O
OppenheimerFunds
New York
|
-$2.83M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$1.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Calamos Advisors
Naperville,
Illinois
| – | -$220K | -7,359 | Closed |
|
102
Principal Financial Group
Des Moines,
Iowa
| – | -$172K | -5,749 | Closed |
|
103
HighTower Advisors
Chicago,
Illinois
| – | -$386K | -5,538 | Closed |
|
|
ECP
104
Empyrean Capital Partners
Los Angeles,
California
| – | -$152K | -5,084 | Closed |
|
105
TD Asset Management
Toronto,
Ontario, Canada
| – | -$99K | -3,305 | Closed |
|
|
VKH
106
Virtu KCG Holdings
New York
| – | -$70K | -2,337 | Closed |
|
107
SG Americas Securities
New York
| – | -$70K | -2,330 | Closed |
|
|
CWM
108
Calamos Wealth Management
Naperville,
Illinois
| – | -$67K | -2,234 | Closed |
|
109
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$56K | -1,879 | Closed |
|
|
LOM
110
Loeb Offshore Management
New York
| – | -$39K | -1,294 | Closed |
|
111
Ameriprise
Minneapolis,
Minnesota
| – | -$23K | -781 | Closed |
|
112
California Public Employees Retirement System
Sacramento,
California
| – | -$15K | -496 | Closed |
|
|
RFC
113
Russell Frank Company
Seattle,
Washington
| – | -$2K | -62 | Closed |
|
MACK Hedge Fund Activity: Q4 2013 in Review
93 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2013, worth a combined $272M — up 36% from $200M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MACK and 18 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 29 added.
The largest buyer was Jennison Associates, adding an estimated $4M. The largest seller was Credit Suisse, cutting an estimated $8.45M.
- 93 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2013, down from 95 in Q3 2013.
- Funds reported $272M of Merrimack Pharmaceuticals, Inc. stock for Q4 2013, up 36% quarter-over-quarter.
- 18 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2013 and 20 closed out, a net change of -2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2013 was Jennison Associates, an estimated $4M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2013 was Credit Suisse, an estimated $8.45M sold.
Based on aggregated 13F filings for Q4 2013.